poisar

Stocks · News reference

Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78

Benzinga Newsdesk

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DFTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Definium Reports Second Phase III Success in Anxiety Disorder Program

    Definium Therapeutics announced positive Phase III results for DT120 ODT in generalized anxiety disorder, with the Panorama study meeting primary and key secondary endpoints. The treatment showed a 5.1-point placebo-adjusted benefit in HAM-A scores at Week 12 with rapid effects by day 2. The company plans an FDA pre-NDA meeting in Q4 2026 and NDA filing in H1 2027, with DT120 also advancing in major depressive disorder and posttraumatic stress disorder trials.

    DFTXPGENACIUALDX